TrumpRx Lists One-Third of Drugs 67–82% Higher Than UK Prices
U.S. site TrumpRx lists cash prices for 54 medicines from 16 manufacturers including Novartis, but a third—such as Pfizer’s Xeljanz and AstraZeneca’s Farxiga—costs 67–82% less under UK NHS net pricing. By capping cash rates rather than insurer reimbursements, TrumpRx sets a price ceiling that could curb Novartis’s U.S. pricing power.
1. TrumpRx Pricing Initiative
TrumpRx was launched in January under most-favored-nation deals with 16 manufacturers including Novartis, aiming to cap U.S. cash prices at or below net prices paid by foreign health systems.
2. UK vs U.S. Price Discrepancies
Comparisons show that 18 of the 54 listed medicines, including arthritis pill Xeljanz and diabetes drug Farxiga, are priced 67–82% lower by the UK’s NHS than on TrumpRx.
3. Manufacturer Impact
By focusing on cash out-of-pocket rates rather than insurer reimbursements, TrumpRx establishes a price ceiling that may constrain U.S. margins for Novartis and its peers, while not affecting covered patient costs.
4. Market Dynamics and Criticism
Critics argue TrumpRx acts as an expensive coupon book, offering discounted cash rates without reducing insurer net prices, and question its effectiveness in lowering overall drug costs for most Americans.